Search

everythinglearnresearchcommunity

for

Search:↓

A 27-year-old male experienced rapid hair loss after dengue fever, which activated a balding gene. The doctor suggested platelet-rich plasma treatment for hair regrowth.

AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.

Finasteride and minoxidil use resulted in a more youthful appearance and improved skin. There is debate about their effects on collagen and skin aging, with no solid evidence supporting significant changes due to finasteride.

Oral minoxidil is discussed, highlighting potential cardiovascular risks at high doses, but users note that lower doses commonly used for hair loss are generally considered safe. Monitoring by doctors is advised, and some users report taking it without issues, comparing its risks to those of common medications like ibuprofen.

The conversation provides tips to reduce facial skin side effects from Minoxidil, such as changing pillowcases, sleeping on the back, careful application, hydration, and taking breaks. One reply suggests that alcohol in Minoxidil formulations, not Minoxidil itself, may cause skin aging.

Fo-Ti is discussed as a potential treatment for hair loss, but its effectiveness is questioned. Users express skepticism and caution about its use.

GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.

Applying Epidermal Growth Factor (EGF) topically may improve skin and potentially promote scalp health and hair growth, especially after microneedling. The user shares their positive experience with EGF and provides a product link.

The user has been using 1mg finasteride and biotin-collagen supplements for 5 months, noticing some progress in hair regrowth. They also use various oils and shampoos, plan to start oral minoxidil, and seek advice on improving their hair care routine.

The use of tropoelastin injections and verteporfin for hair transplant recipients to help regrow donor area hairs, as well as research done on tropoelastin injections restoring elastin in scarred heart tissue and skin. There are discussions about why it is taking so long to get cosmetic mass produced tropoelastin injectables on the market.

New hair loss treatments PP405 and VDPHL01 are discussed with skepticism and hope, alongside existing treatments like minoxidil and finasteride. Users express frustration over limited progress since the 1980s but remain cautiously optimistic.

The conversation discusses using microneedling with growth factor serum, PRF injections, dutasteride, oral and topical minoxidil, and topical exosomes to treat hair loss, particularly on the crown. OP plans to microneedle twice a month and seeks feedback on Korean growth factor serums.

The conversation discusses the potential of Verteporfin for hair regeneration and improving hair transplant surgery to leave no scars. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

Vitamin D deficiency is linked to hair loss, and supplementation with vitamin D can improve conditions like androgenic alopecia and telogen effluvium. Users discussed various dosages of vitamin D, emphasizing the importance of getting blood tests to determine the appropriate amount.

Dr. Bloxham's trial is testing verteporfin on hair transplant patients to see if it can improve hair regrowth in treated areas. People are discussing the potential for follicle regeneration, expected results timeline, and concerns about side effects like cancer.

The conversation discusses a new product from Actifolic, which combines RU58841 and GHK-CU for hair loss treatment. The participants are considering whether it's worth trying.

A user's hair growth progress over 5 months using Fin 2.5mg gel and Redensyl serum, with the user noticing baby hairs and an improvement in thickness. Another user asked what redensyl serum was and the response was appreciation for noticing the hair loss early on.

Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.

A compound called MTP3 from the Monoterpene family was found to be safe and highly effective at treating hair loss by inhibiting the FGF5 gene, but its identity is undisclosed for commercial reasons. No specific treatments like Minoxidil, finasteride, or RU58841 were discussed.

Aminexil/Kopexil may help reduce hair loss by addressing perifollicular fibrosis in androgenetic alopecia, but it lacks the extensive clinical backing of finasteride and minoxidil. Some users find it effective, but availability and cost are issues, especially in the US where it's not FDA-approved.

The user experienced new hair growth after switching from oral finasteride to topical RU58841 with minoxidil and undergoing stem cell therapy. They noticed new hairs at the hairline and temples, but are unsure which treatment is responsible.

The post discusses the user's experience with hair loss treatment RU58841, which was tested for quality and found to be 96+% pure. The conversation includes various responses, with some users questioning the safety of the product and others expressing satisfaction with the test results.

The conversation discusses the use of Verteporfin in hair loss treatment. It suggests that Verteporfin could potentially regenerate hair follicles instead of forming scars, providing an unlimited donor supply for hair transplants.

The post discusses a user's six-year progress with finasteride and a Follicular Unit Transplant (FUT) for hair loss. The user shared before and after photos in reverse order, leading to confusion, but overall, the community responded positively to the user's hair regrowth.

GT20029 is discussed as a potential treatment for androgenetic hair loss by targeting androgen receptors, unlike finasteride which reduces DHT broadly. Concerns include its effectiveness, genetic variations in androgen receptors, and availability, with some skepticism about its potential as a true alternative.

Amplifica starting clinical trials for new hair loss drug. SCUBE3 protein discovered, stimulates hair growth, could be alternative to Minoxidil and Finasteride.

A user who didn't respond well to minoxidil and finasteride is considering the role of IGF-1 in hair loss treatment effectiveness. They discuss the potential of using HGH to improve hair growth and other health issues, referencing several sources that suggest IGF-1 levels may influence hair loss and treatment response.

Balding scalps have more androgen receptors, leading to increased TGF-beta, which causes blood vessel loss and hair follicle miniaturization. Blocking androgen signaling and TGF-beta may help prevent hair loss.

Hair loss treatments like GT20029, pyrilutamide, and Follica show promise in 2022. Phase 1 and 2 trials are underway, and new hair growth studies have been published.

Finasteride and dutasteride can improve skin texture and reduce acne by lowering DHT but do not reverse aging. They may enhance skin and hair health for some, but can also cause side effects like dry skin and sexual dysfunction.